Podcasts about ceacam5

Featuring perspectives from Dr Melissa Johnson, including the following topics: Role of biomarker testing in optimal selection of first-line therapy for patients with non-small cell lung cancer (NSCLC) (0:00) Efficacy and safety with datopotamab deruxtecan for previously treated NSCLC (15:45) Antitumor activity with and current status of CEACAM5-targeted therapy for relapsed NSCLC (30:24) Evolution of drug development and clinical research (37:56) Key findings with sacituzumab govitecan for NSCLC (41:59) Telisotuzumab vedotin for patients with NSCLC and MET expression (48:44) Recent findings with tumor treating fields for metastatic NSCLC after disease progression on platinum-based therapy (50:49) Other novel antibody-drug conjugates under investigation for NSCLC (55:26) Case: A woman in her mid 50s with recurrent extensive-stage small cell lung cancer who developed pneumonitis on ifinatamab deruxtecan (59:05) Case: A woman in her early 60s with complete response to dose-reduced patritumab deruxtecan (1:00:15) CME information and select publications  

David Planchard, MD, PhD - Catching Up on CEACAM5 in NSCLC: The Whys and Hows of Detection and Targeting

David Planchard, MD, PhD - Catching Up on CEACAM5 in NSCLC: The Whys and Hows of Detection and Targeting

David Planchard, MD, PhD - Catching Up on CEACAM5 in NSCLC: The Whys and Hows of Detection and Targeting

David Planchard, MD, PhD - Catching Up on CEACAM5 in NSCLC: The Whys and Hows of Detection and Targeting

David Planchard, MD, PhD - Catching Up on CEACAM5 in NSCLC: The Whys and Hows of Detection and Targeting

David Planchard, MD, PhD - Catching Up on CEACAM5 in NSCLC: The Whys and Hows of Detection and Targeting

Go online to PeerView.com/YEN860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Mounting evidence continues to elucidate the clinical potential of antibody–drug conjugates (ADCs) in the treatment of patients with lung cancer. ADCs are now transitioning from research settings to clinical practice, with the first approval of a novel HER2-targeting ADC, trastuzumab deruxtecan, for HER2-mutated NSCLC. In addition, various other potent ADCs targeting HER3, TROP2, CEACAM5, c-MET, AXL, ROR2, and others are being evaluated in clinical trials in different disease settings, including in patients with advanced NSCLC with and without actionable genomic alterations, and they are showing impressive activity. How do we realize the promise of these ADCs as the next frontier in precision lung cancer care? What are the best ways to apply the emerging science to patient care decisions in everyday practice? These and other key questions are addressed in this activity, which is based on a recent live symposium and produced in collaboration with the LUNGevity Foundation to highlight patient perspectives alongside those of clinicians. Leading experts in the field share their interpretations of the latest practice-changing evidence and provide practical guidance using real-world case scenarios to demonstrate how to maximize beneficial patient outcomes using ADCs. Upon completion of this activity, participants should be better able to: Discuss the modern composition, rationale for use, and clinical potential of novel ADCs in NSCLC; Compare the characteristics, efficacy/safety, and ongoing investigations of novel ADCs in NSCLC; Apply the latest evidence and guidelines on patient assessment in NSCLC, including biomarker testing as indicated, to identify patients for targeted therapies, including novel ADCs; and Utilize best practices for identifying and managing treatment-related adverse events in patients receiving targeted therapies for NSCLC to promote optimal adherence, outcomes, and quality of life

Go online to PeerView.com/YEN860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Mounting evidence continues to elucidate the clinical potential of antibody–drug conjugates (ADCs) in the treatment of patients with lung cancer. ADCs are now transitioning from research settings to clinical practice, with the first approval of a novel HER2-targeting ADC, trastuzumab deruxtecan, for HER2-mutated NSCLC. In addition, various other potent ADCs targeting HER3, TROP2, CEACAM5, c-MET, AXL, ROR2, and others are being evaluated in clinical trials in different disease settings, including in patients with advanced NSCLC with and without actionable genomic alterations, and they are showing impressive activity. How do we realize the promise of these ADCs as the next frontier in precision lung cancer care? What are the best ways to apply the emerging science to patient care decisions in everyday practice? These and other key questions are addressed in this activity, which is based on a recent live symposium and produced in collaboration with the LUNGevity Foundation to highlight patient perspectives alongside those of clinicians. Leading experts in the field share their interpretations of the latest practice-changing evidence and provide practical guidance using real-world case scenarios to demonstrate how to maximize beneficial patient outcomes using ADCs. Upon completion of this activity, participants should be better able to: Discuss the modern composition, rationale for use, and clinical potential of novel ADCs in NSCLC; Compare the characteristics, efficacy/safety, and ongoing investigations of novel ADCs in NSCLC; Apply the latest evidence and guidelines on patient assessment in NSCLC, including biomarker testing as indicated, to identify patients for targeted therapies, including novel ADCs; and Utilize best practices for identifying and managing treatment-related adverse events in patients receiving targeted therapies for NSCLC to promote optimal adherence, outcomes, and quality of life

Go online to PeerView.com/YEN860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Mounting evidence continues to elucidate the clinical potential of antibody–drug conjugates (ADCs) in the treatment of patients with lung cancer. ADCs are now transitioning from research settings to clinical practice, with the first approval of a novel HER2-targeting ADC, trastuzumab deruxtecan, for HER2-mutated NSCLC. In addition, various other potent ADCs targeting HER3, TROP2, CEACAM5, c-MET, AXL, ROR2, and others are being evaluated in clinical trials in different disease settings, including in patients with advanced NSCLC with and without actionable genomic alterations, and they are showing impressive activity. How do we realize the promise of these ADCs as the next frontier in precision lung cancer care? What are the best ways to apply the emerging science to patient care decisions in everyday practice? These and other key questions are addressed in this activity, which is based on a recent live symposium and produced in collaboration with the LUNGevity Foundation to highlight patient perspectives alongside those of clinicians. Leading experts in the field share their interpretations of the latest practice-changing evidence and provide practical guidance using real-world case scenarios to demonstrate how to maximize beneficial patient outcomes using ADCs. Upon completion of this activity, participants should be better able to: Discuss the modern composition, rationale for use, and clinical potential of novel ADCs in NSCLC; Compare the characteristics, efficacy/safety, and ongoing investigations of novel ADCs in NSCLC; Apply the latest evidence and guidelines on patient assessment in NSCLC, including biomarker testing as indicated, to identify patients for targeted therapies, including novel ADCs; and Utilize best practices for identifying and managing treatment-related adverse events in patients receiving targeted therapies for NSCLC to promote optimal adherence, outcomes, and quality of life

Go online to PeerView.com/YEN860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Mounting evidence continues to elucidate the clinical potential of antibody–drug conjugates (ADCs) in the treatment of patients with lung cancer. ADCs are now transitioning from research settings to clinical practice, with the first approval of a novel HER2-targeting ADC, trastuzumab deruxtecan, for HER2-mutated NSCLC. In addition, various other potent ADCs targeting HER3, TROP2, CEACAM5, c-MET, AXL, ROR2, and others are being evaluated in clinical trials in different disease settings, including in patients with advanced NSCLC with and without actionable genomic alterations, and they are showing impressive activity. How do we realize the promise of these ADCs as the next frontier in precision lung cancer care? What are the best ways to apply the emerging science to patient care decisions in everyday practice? These and other key questions are addressed in this activity, which is based on a recent live symposium and produced in collaboration with the LUNGevity Foundation to highlight patient perspectives alongside those of clinicians. Leading experts in the field share their interpretations of the latest practice-changing evidence and provide practical guidance using real-world case scenarios to demonstrate how to maximize beneficial patient outcomes using ADCs. Upon completion of this activity, participants should be better able to: Discuss the modern composition, rationale for use, and clinical potential of novel ADCs in NSCLC; Compare the characteristics, efficacy/safety, and ongoing investigations of novel ADCs in NSCLC; Apply the latest evidence and guidelines on patient assessment in NSCLC, including biomarker testing as indicated, to identify patients for targeted therapies, including novel ADCs; and Utilize best practices for identifying and managing treatment-related adverse events in patients receiving targeted therapies for NSCLC to promote optimal adherence, outcomes, and quality of life

Go online to PeerView.com/YEN860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Mounting evidence continues to elucidate the clinical potential of antibody–drug conjugates (ADCs) in the treatment of patients with lung cancer. ADCs are now transitioning from research settings to clinical practice, with the first approval of a novel HER2-targeting ADC, trastuzumab deruxtecan, for HER2-mutated NSCLC. In addition, various other potent ADCs targeting HER3, TROP2, CEACAM5, c-MET, AXL, ROR2, and others are being evaluated in clinical trials in different disease settings, including in patients with advanced NSCLC with and without actionable genomic alterations, and they are showing impressive activity. How do we realize the promise of these ADCs as the next frontier in precision lung cancer care? What are the best ways to apply the emerging science to patient care decisions in everyday practice? These and other key questions are addressed in this activity, which is based on a recent live symposium and produced in collaboration with the LUNGevity Foundation to highlight patient perspectives alongside those of clinicians. Leading experts in the field share their interpretations of the latest practice-changing evidence and provide practical guidance using real-world case scenarios to demonstrate how to maximize beneficial patient outcomes using ADCs. Upon completion of this activity, participants should be better able to: Discuss the modern composition, rationale for use, and clinical potential of novel ADCs in NSCLC; Compare the characteristics, efficacy/safety, and ongoing investigations of novel ADCs in NSCLC; Apply the latest evidence and guidelines on patient assessment in NSCLC, including biomarker testing as indicated, to identify patients for targeted therapies, including novel ADCs; and Utilize best practices for identifying and managing treatment-related adverse events in patients receiving targeted therapies for NSCLC to promote optimal adherence, outcomes, and quality of life

Go online to PeerView.com/YEN860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Mounting evidence continues to elucidate the clinical potential of antibody–drug conjugates (ADCs) in the treatment of patients with lung cancer. ADCs are now transitioning from research settings to clinical practice, with the first approval of a novel HER2-targeting ADC, trastuzumab deruxtecan, for HER2-mutated NSCLC. In addition, various other potent ADCs targeting HER3, TROP2, CEACAM5, c-MET, AXL, ROR2, and others are being evaluated in clinical trials in different disease settings, including in patients with advanced NSCLC with and without actionable genomic alterations, and they are showing impressive activity. How do we realize the promise of these ADCs as the next frontier in precision lung cancer care? What are the best ways to apply the emerging science to patient care decisions in everyday practice? These and other key questions are addressed in this activity, which is based on a recent live symposium and produced in collaboration with the LUNGevity Foundation to highlight patient perspectives alongside those of clinicians. Leading experts in the field share their interpretations of the latest practice-changing evidence and provide practical guidance using real-world case scenarios to demonstrate how to maximize beneficial patient outcomes using ADCs. Upon completion of this activity, participants should be better able to: Discuss the modern composition, rationale for use, and clinical potential of novel ADCs in NSCLC; Compare the characteristics, efficacy/safety, and ongoing investigations of novel ADCs in NSCLC; Apply the latest evidence and guidelines on patient assessment in NSCLC, including biomarker testing as indicated, to identify patients for targeted therapies, including novel ADCs; and Utilize best practices for identifying and managing treatment-related adverse events in patients receiving targeted therapies for NSCLC to promote optimal adherence, outcomes, and quality of life

Go online to PeerView.com/YEN860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Mounting evidence continues to elucidate the clinical potential of antibody–drug conjugates (ADCs) in the treatment of patients with lung cancer. ADCs are now transitioning from research settings to clinical practice, with the first approval of a novel HER2-targeting ADC, trastuzumab deruxtecan, for HER2-mutated NSCLC. In addition, various other potent ADCs targeting HER3, TROP2, CEACAM5, c-MET, AXL, ROR2, and others are being evaluated in clinical trials in different disease settings, including in patients with advanced NSCLC with and without actionable genomic alterations, and they are showing impressive activity. How do we realize the promise of these ADCs as the next frontier in precision lung cancer care? What are the best ways to apply the emerging science to patient care decisions in everyday practice? These and other key questions are addressed in this activity, which is based on a recent live symposium and produced in collaboration with the LUNGevity Foundation to highlight patient perspectives alongside those of clinicians. Leading experts in the field share their interpretations of the latest practice-changing evidence and provide practical guidance using real-world case scenarios to demonstrate how to maximize beneficial patient outcomes using ADCs. Upon completion of this activity, participants should be better able to: Discuss the modern composition, rationale for use, and clinical potential of novel ADCs in NSCLC; Compare the characteristics, efficacy/safety, and ongoing investigations of novel ADCs in NSCLC; Apply the latest evidence and guidelines on patient assessment in NSCLC, including biomarker testing as indicated, to identify patients for targeted therapies, including novel ADCs; and Utilize best practices for identifying and managing treatment-related adverse events in patients receiving targeted therapies for NSCLC to promote optimal adherence, outcomes, and quality of life

Go online to PeerView.com/YEN860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Mounting evidence continues to elucidate the clinical potential of antibody–drug conjugates (ADCs) in the treatment of patients with lung cancer. ADCs are now transitioning from research settings to clinical practice, with the first approval of a novel HER2-targeting ADC, trastuzumab deruxtecan, for HER2-mutated NSCLC. In addition, various other potent ADCs targeting HER3, TROP2, CEACAM5, c-MET, AXL, ROR2, and others are being evaluated in clinical trials in different disease settings, including in patients with advanced NSCLC with and without actionable genomic alterations, and they are showing impressive activity. How do we realize the promise of these ADCs as the next frontier in precision lung cancer care? What are the best ways to apply the emerging science to patient care decisions in everyday practice? These and other key questions are addressed in this activity, which is based on a recent live symposium and produced in collaboration with the LUNGevity Foundation to highlight patient perspectives alongside those of clinicians. Leading experts in the field share their interpretations of the latest practice-changing evidence and provide practical guidance using real-world case scenarios to demonstrate how to maximize beneficial patient outcomes using ADCs. Upon completion of this activity, participants should be better able to: Discuss the modern composition, rationale for use, and clinical potential of novel ADCs in NSCLC; Compare the characteristics, efficacy/safety, and ongoing investigations of novel ADCs in NSCLC; Apply the latest evidence and guidelines on patient assessment in NSCLC, including biomarker testing as indicated, to identify patients for targeted therapies, including novel ADCs; and Utilize best practices for identifying and managing treatment-related adverse events in patients receiving targeted therapies for NSCLC to promote optimal adherence, outcomes, and quality of life

Go online to PeerView.com/PJD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. New, modern antibody–drug conjugates (ADCs) have emerged as promising additions to the treatment arsenal for patients with lung cancer, with the first HER2-targeting ADC recently gaining FDA approval for patients with unresectable or metastatic NSCLC whose tumors have HER2 mutations. Clinical trials are also underway with novel ADCs targeting HER3, TROP2, CEACAM5, and MET, among others, and have been yielding encouraging results to date. What are the unique structural and mechanistic features as well as efficacy and safety profiles of these ADCs? Where are they likely to best fit in the NSCLC treatment algorithms? What practical considerations should be taken into account when integrating these therapies into treatment plans? These and other topics are explored in this unique educational activity, based on a recent live symposium, in which experts compete to answer a series of challenge questions that frame explanatory evidence and panel discussions focused on the growing role and impact of ADCs in the treatment of NSCLC. Upon completion of this activity, participants should be better able to: Discuss the clinical importance and biologic rationale for targeting of HER2, HER3, TROP2, and other alterations with novel ADCs in lung cancer; Summarize the characteristics, mechanisms of action, and latest safety and efficacy of ADCs targeting HER2, HER3, TROP2, and other alterations in NSCLC; Apply the latest evidence and guidelines on patient assessment in NSCLC, including biomarker testing as indicated, to identify patients for novel ADCs and other targeted therapies; and Implement multidisciplinary and patient-centric approaches to effectively and safely integrate HER2-, HER3-, and TROP2-targeted and other novel ADCs into treatment plans for appropriate patients with NSCLC

Go online to PeerView.com/PJD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. New, modern antibody–drug conjugates (ADCs) have emerged as promising additions to the treatment arsenal for patients with lung cancer, with the first HER2-targeting ADC recently gaining FDA approval for patients with unresectable or metastatic NSCLC whose tumors have HER2 mutations. Clinical trials are also underway with novel ADCs targeting HER3, TROP2, CEACAM5, and MET, among others, and have been yielding encouraging results to date. What are the unique structural and mechanistic features as well as efficacy and safety profiles of these ADCs? Where are they likely to best fit in the NSCLC treatment algorithms? What practical considerations should be taken into account when integrating these therapies into treatment plans? These and other topics are explored in this unique educational activity, based on a recent live symposium, in which experts compete to answer a series of challenge questions that frame explanatory evidence and panel discussions focused on the growing role and impact of ADCs in the treatment of NSCLC. Upon completion of this activity, participants should be better able to: Discuss the clinical importance and biologic rationale for targeting of HER2, HER3, TROP2, and other alterations with novel ADCs in lung cancer; Summarize the characteristics, mechanisms of action, and latest safety and efficacy of ADCs targeting HER2, HER3, TROP2, and other alterations in NSCLC; Apply the latest evidence and guidelines on patient assessment in NSCLC, including biomarker testing as indicated, to identify patients for novel ADCs and other targeted therapies; and Implement multidisciplinary and patient-centric approaches to effectively and safely integrate HER2-, HER3-, and TROP2-targeted and other novel ADCs into treatment plans for appropriate patients with NSCLC

Go online to PeerView.com/PJD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. New, modern antibody–drug conjugates (ADCs) have emerged as promising additions to the treatment arsenal for patients with lung cancer, with the first HER2-targeting ADC recently gaining FDA approval for patients with unresectable or metastatic NSCLC whose tumors have HER2 mutations. Clinical trials are also underway with novel ADCs targeting HER3, TROP2, CEACAM5, and MET, among others, and have been yielding encouraging results to date. What are the unique structural and mechanistic features as well as efficacy and safety profiles of these ADCs? Where are they likely to best fit in the NSCLC treatment algorithms? What practical considerations should be taken into account when integrating these therapies into treatment plans? These and other topics are explored in this unique educational activity, based on a recent live symposium, in which experts compete to answer a series of challenge questions that frame explanatory evidence and panel discussions focused on the growing role and impact of ADCs in the treatment of NSCLC. Upon completion of this activity, participants should be better able to: Discuss the clinical importance and biologic rationale for targeting of HER2, HER3, TROP2, and other alterations with novel ADCs in lung cancer; Summarize the characteristics, mechanisms of action, and latest safety and efficacy of ADCs targeting HER2, HER3, TROP2, and other alterations in NSCLC; Apply the latest evidence and guidelines on patient assessment in NSCLC, including biomarker testing as indicated, to identify patients for novel ADCs and other targeted therapies; and Implement multidisciplinary and patient-centric approaches to effectively and safely integrate HER2-, HER3-, and TROP2-targeted and other novel ADCs into treatment plans for appropriate patients with NSCLC

Go online to PeerView.com/PJD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. New, modern antibody–drug conjugates (ADCs) have emerged as promising additions to the treatment arsenal for patients with lung cancer, with the first HER2-targeting ADC recently gaining FDA approval for patients with unresectable or metastatic NSCLC whose tumors have HER2 mutations. Clinical trials are also underway with novel ADCs targeting HER3, TROP2, CEACAM5, and MET, among others, and have been yielding encouraging results to date. What are the unique structural and mechanistic features as well as efficacy and safety profiles of these ADCs? Where are they likely to best fit in the NSCLC treatment algorithms? What practical considerations should be taken into account when integrating these therapies into treatment plans? These and other topics are explored in this unique educational activity, based on a recent live symposium, in which experts compete to answer a series of challenge questions that frame explanatory evidence and panel discussions focused on the growing role and impact of ADCs in the treatment of NSCLC. Upon completion of this activity, participants should be better able to: Discuss the clinical importance and biologic rationale for targeting of HER2, HER3, TROP2, and other alterations with novel ADCs in lung cancer; Summarize the characteristics, mechanisms of action, and latest safety and efficacy of ADCs targeting HER2, HER3, TROP2, and other alterations in NSCLC; Apply the latest evidence and guidelines on patient assessment in NSCLC, including biomarker testing as indicated, to identify patients for novel ADCs and other targeted therapies; and Implement multidisciplinary and patient-centric approaches to effectively and safely integrate HER2-, HER3-, and TROP2-targeted and other novel ADCs into treatment plans for appropriate patients with NSCLC

Go online to PeerView.com/PJD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. New, modern antibody–drug conjugates (ADCs) have emerged as promising additions to the treatment arsenal for patients with lung cancer, with the first HER2-targeting ADC recently gaining FDA approval for patients with unresectable or metastatic NSCLC whose tumors have HER2 mutations. Clinical trials are also underway with novel ADCs targeting HER3, TROP2, CEACAM5, and MET, among others, and have been yielding encouraging results to date. What are the unique structural and mechanistic features as well as efficacy and safety profiles of these ADCs? Where are they likely to best fit in the NSCLC treatment algorithms? What practical considerations should be taken into account when integrating these therapies into treatment plans? These and other topics are explored in this unique educational activity, based on a recent live symposium, in which experts compete to answer a series of challenge questions that frame explanatory evidence and panel discussions focused on the growing role and impact of ADCs in the treatment of NSCLC. Upon completion of this activity, participants should be better able to: Discuss the clinical importance and biologic rationale for targeting of HER2, HER3, TROP2, and other alterations with novel ADCs in lung cancer; Summarize the characteristics, mechanisms of action, and latest safety and efficacy of ADCs targeting HER2, HER3, TROP2, and other alterations in NSCLC; Apply the latest evidence and guidelines on patient assessment in NSCLC, including biomarker testing as indicated, to identify patients for novel ADCs and other targeted therapies; and Implement multidisciplinary and patient-centric approaches to effectively and safely integrate HER2-, HER3-, and TROP2-targeted and other novel ADCs into treatment plans for appropriate patients with NSCLC

Go online to PeerView.com/PJD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. New, modern antibody–drug conjugates (ADCs) have emerged as promising additions to the treatment arsenal for patients with lung cancer, with the first HER2-targeting ADC recently gaining FDA approval for patients with unresectable or metastatic NSCLC whose tumors have HER2 mutations. Clinical trials are also underway with novel ADCs targeting HER3, TROP2, CEACAM5, and MET, among others, and have been yielding encouraging results to date. What are the unique structural and mechanistic features as well as efficacy and safety profiles of these ADCs? Where are they likely to best fit in the NSCLC treatment algorithms? What practical considerations should be taken into account when integrating these therapies into treatment plans? These and other topics are explored in this unique educational activity, based on a recent live symposium, in which experts compete to answer a series of challenge questions that frame explanatory evidence and panel discussions focused on the growing role and impact of ADCs in the treatment of NSCLC. Upon completion of this activity, participants should be better able to: Discuss the clinical importance and biologic rationale for targeting of HER2, HER3, TROP2, and other alterations with novel ADCs in lung cancer; Summarize the characteristics, mechanisms of action, and latest safety and efficacy of ADCs targeting HER2, HER3, TROP2, and other alterations in NSCLC; Apply the latest evidence and guidelines on patient assessment in NSCLC, including biomarker testing as indicated, to identify patients for novel ADCs and other targeted therapies; and Implement multidisciplinary and patient-centric approaches to effectively and safely integrate HER2-, HER3-, and TROP2-targeted and other novel ADCs into treatment plans for appropriate patients with NSCLC

Go online to PeerView.com/PJD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. New, modern antibody–drug conjugates (ADCs) have emerged as promising additions to the treatment arsenal for patients with lung cancer, with the first HER2-targeting ADC recently gaining FDA approval for patients with unresectable or metastatic NSCLC whose tumors have HER2 mutations. Clinical trials are also underway with novel ADCs targeting HER3, TROP2, CEACAM5, and MET, among others, and have been yielding encouraging results to date. What are the unique structural and mechanistic features as well as efficacy and safety profiles of these ADCs? Where are they likely to best fit in the NSCLC treatment algorithms? What practical considerations should be taken into account when integrating these therapies into treatment plans? These and other topics are explored in this unique educational activity, based on a recent live symposium, in which experts compete to answer a series of challenge questions that frame explanatory evidence and panel discussions focused on the growing role and impact of ADCs in the treatment of NSCLC. Upon completion of this activity, participants should be better able to: Discuss the clinical importance and biologic rationale for targeting of HER2, HER3, TROP2, and other alterations with novel ADCs in lung cancer; Summarize the characteristics, mechanisms of action, and latest safety and efficacy of ADCs targeting HER2, HER3, TROP2, and other alterations in NSCLC; Apply the latest evidence and guidelines on patient assessment in NSCLC, including biomarker testing as indicated, to identify patients for novel ADCs and other targeted therapies; and Implement multidisciplinary and patient-centric approaches to effectively and safely integrate HER2-, HER3-, and TROP2-targeted and other novel ADCs into treatment plans for appropriate patients with NSCLC

Go online to PeerView.com/PJD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. New, modern antibody–drug conjugates (ADCs) have emerged as promising additions to the treatment arsenal for patients with lung cancer, with the first HER2-targeting ADC recently gaining FDA approval for patients with unresectable or metastatic NSCLC whose tumors have HER2 mutations. Clinical trials are also underway with novel ADCs targeting HER3, TROP2, CEACAM5, and MET, among others, and have been yielding encouraging results to date. What are the unique structural and mechanistic features as well as efficacy and safety profiles of these ADCs? Where are they likely to best fit in the NSCLC treatment algorithms? What practical considerations should be taken into account when integrating these therapies into treatment plans? These and other topics are explored in this unique educational activity, based on a recent live symposium, in which experts compete to answer a series of challenge questions that frame explanatory evidence and panel discussions focused on the growing role and impact of ADCs in the treatment of NSCLC. Upon completion of this activity, participants should be better able to: Discuss the clinical importance and biologic rationale for targeting of HER2, HER3, TROP2, and other alterations with novel ADCs in lung cancer; Summarize the characteristics, mechanisms of action, and latest safety and efficacy of ADCs targeting HER2, HER3, TROP2, and other alterations in NSCLC; Apply the latest evidence and guidelines on patient assessment in NSCLC, including biomarker testing as indicated, to identify patients for novel ADCs and other targeted therapies; and Implement multidisciplinary and patient-centric approaches to effectively and safely integrate HER2-, HER3-, and TROP2-targeted and other novel ADCs into treatment plans for appropriate patients with NSCLC

Dr Dy discusses the development of CEACAM5-directed antibody-drug conjugates in non–small cell lung cancer, ongoing research with tusamitamab ravtansine, and the potential role of competing docetaxel-based combination strategies in the second-line setting.

Go online to PeerView.com/FVE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Mounting evidence continues to support the clinical potential of antibody–drug conjugates (ADCs) in the treatment of patients with lung cancer, bringing hope to patients with limited treatment options. For example, novel HER2-targeting ADCs have demonstrated remarkable efficacy in advanced NSCLC, particularly in patients with HER2 mutations. ADCs targeting HER3, TROP2, and other alterations (eg, CEACAM5 and MET) are also producing promising data. In the context of these advances, it is important to learn to identify the right patients who are most likely to benefit from these therapies and determine where within the NSCLC treatment arsenal these therapies fit the best. Watch PeerView's latest educational video, based on a recent live symposium, which combines high-level seminars highlighting the latest evidence on HER2-, HER3-, and TROP2-targeting ADCs in NSCLC with a practicum dedicated to providing useful guidance on the implications and applications of the science to modern oncology practice to improve outcomes in patients with lung cancer. Upon completion of this activity, participants should be better able to: Discuss the frequency, role, and targetable potential of HER2, HER3, TROP2, and other alterations in NSCLC; Compare the characteristics, efficacy/safety, and ongoing investigations of emerging ADCs targeting HER2, HER3, TROP2, and other alterations in NSCLC; Apply the latest evidence and guidelines on patient assessment in NSCLC, including biomarker testing as indicated, to identify patients for targeted therapies, including emerging ADCs targeting HER2, HER3, TROP2, and other alterations in the context of a clinical trial; Utilize best practices for identifying and managing treatment-related adverse events in patients receiving targeted therapies for NSCLC to promote optimal adherence, outcomes, and quality of life

Go online to PeerView.com/FVE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Mounting evidence continues to support the clinical potential of antibody–drug conjugates (ADCs) in the treatment of patients with lung cancer, bringing hope to patients with limited treatment options. For example, novel HER2-targeting ADCs have demonstrated remarkable efficacy in advanced NSCLC, particularly in patients with HER2 mutations. ADCs targeting HER3, TROP2, and other alterations (eg, CEACAM5 and MET) are also producing promising data. In the context of these advances, it is important to learn to identify the right patients who are most likely to benefit from these therapies and determine where within the NSCLC treatment arsenal these therapies fit the best. Watch PeerView's latest educational video, based on a recent live symposium, which combines high-level seminars highlighting the latest evidence on HER2-, HER3-, and TROP2-targeting ADCs in NSCLC with a practicum dedicated to providing useful guidance on the implications and applications of the science to modern oncology practice to improve outcomes in patients with lung cancer. Upon completion of this activity, participants should be better able to: Discuss the frequency, role, and targetable potential of HER2, HER3, TROP2, and other alterations in NSCLC; Compare the characteristics, efficacy/safety, and ongoing investigations of emerging ADCs targeting HER2, HER3, TROP2, and other alterations in NSCLC; Apply the latest evidence and guidelines on patient assessment in NSCLC, including biomarker testing as indicated, to identify patients for targeted therapies, including emerging ADCs targeting HER2, HER3, TROP2, and other alterations in the context of a clinical trial; Utilize best practices for identifying and managing treatment-related adverse events in patients receiving targeted therapies for NSCLC to promote optimal adherence, outcomes, and quality of life

Go online to PeerView.com/FVE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Mounting evidence continues to support the clinical potential of antibody–drug conjugates (ADCs) in the treatment of patients with lung cancer, bringing hope to patients with limited treatment options. For example, novel HER2-targeting ADCs have demonstrated remarkable efficacy in advanced NSCLC, particularly in patients with HER2 mutations. ADCs targeting HER3, TROP2, and other alterations (eg, CEACAM5 and MET) are also producing promising data. In the context of these advances, it is important to learn to identify the right patients who are most likely to benefit from these therapies and determine where within the NSCLC treatment arsenal these therapies fit the best. Watch PeerView's latest educational video, based on a recent live symposium, which combines high-level seminars highlighting the latest evidence on HER2-, HER3-, and TROP2-targeting ADCs in NSCLC with a practicum dedicated to providing useful guidance on the implications and applications of the science to modern oncology practice to improve outcomes in patients with lung cancer. Upon completion of this activity, participants should be better able to: Discuss the frequency, role, and targetable potential of HER2, HER3, TROP2, and other alterations in NSCLC; Compare the characteristics, efficacy/safety, and ongoing investigations of emerging ADCs targeting HER2, HER3, TROP2, and other alterations in NSCLC; Apply the latest evidence and guidelines on patient assessment in NSCLC, including biomarker testing as indicated, to identify patients for targeted therapies, including emerging ADCs targeting HER2, HER3, TROP2, and other alterations in the context of a clinical trial; Utilize best practices for identifying and managing treatment-related adverse events in patients receiving targeted therapies for NSCLC to promote optimal adherence, outcomes, and quality of life

Go online to PeerView.com/FVE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Mounting evidence continues to support the clinical potential of antibody–drug conjugates (ADCs) in the treatment of patients with lung cancer, bringing hope to patients with limited treatment options. For example, novel HER2-targeting ADCs have demonstrated remarkable efficacy in advanced NSCLC, particularly in patients with HER2 mutations. ADCs targeting HER3, TROP2, and other alterations (eg, CEACAM5 and MET) are also producing promising data. In the context of these advances, it is important to learn to identify the right patients who are most likely to benefit from these therapies and determine where within the NSCLC treatment arsenal these therapies fit the best. Watch PeerView's latest educational video, based on a recent live symposium, which combines high-level seminars highlighting the latest evidence on HER2-, HER3-, and TROP2-targeting ADCs in NSCLC with a practicum dedicated to providing useful guidance on the implications and applications of the science to modern oncology practice to improve outcomes in patients with lung cancer. Upon completion of this activity, participants should be better able to: Discuss the frequency, role, and targetable potential of HER2, HER3, TROP2, and other alterations in NSCLC; Compare the characteristics, efficacy/safety, and ongoing investigations of emerging ADCs targeting HER2, HER3, TROP2, and other alterations in NSCLC; Apply the latest evidence and guidelines on patient assessment in NSCLC, including biomarker testing as indicated, to identify patients for targeted therapies, including emerging ADCs targeting HER2, HER3, TROP2, and other alterations in the context of a clinical trial; Utilize best practices for identifying and managing treatment-related adverse events in patients receiving targeted therapies for NSCLC to promote optimal adherence, outcomes, and quality of life

Go online to PeerView.com/FVE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Mounting evidence continues to support the clinical potential of antibody–drug conjugates (ADCs) in the treatment of patients with lung cancer, bringing hope to patients with limited treatment options. For example, novel HER2-targeting ADCs have demonstrated remarkable efficacy in advanced NSCLC, particularly in patients with HER2 mutations. ADCs targeting HER3, TROP2, and other alterations (eg, CEACAM5 and MET) are also producing promising data. In the context of these advances, it is important to learn to identify the right patients who are most likely to benefit from these therapies and determine where within the NSCLC treatment arsenal these therapies fit the best. Watch PeerView's latest educational video, based on a recent live symposium, which combines high-level seminars highlighting the latest evidence on HER2-, HER3-, and TROP2-targeting ADCs in NSCLC with a practicum dedicated to providing useful guidance on the implications and applications of the science to modern oncology practice to improve outcomes in patients with lung cancer. Upon completion of this activity, participants should be better able to: Discuss the frequency, role, and targetable potential of HER2, HER3, TROP2, and other alterations in NSCLC; Compare the characteristics, efficacy/safety, and ongoing investigations of emerging ADCs targeting HER2, HER3, TROP2, and other alterations in NSCLC; Apply the latest evidence and guidelines on patient assessment in NSCLC, including biomarker testing as indicated, to identify patients for targeted therapies, including emerging ADCs targeting HER2, HER3, TROP2, and other alterations in the context of a clinical trial; Utilize best practices for identifying and managing treatment-related adverse events in patients receiving targeted therapies for NSCLC to promote optimal adherence, outcomes, and quality of life

Go online to PeerView.com/FVE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Mounting evidence continues to support the clinical potential of antibody–drug conjugates (ADCs) in the treatment of patients with lung cancer, bringing hope to patients with limited treatment options. For example, novel HER2-targeting ADCs have demonstrated remarkable efficacy in advanced NSCLC, particularly in patients with HER2 mutations. ADCs targeting HER3, TROP2, and other alterations (eg, CEACAM5 and MET) are also producing promising data. In the context of these advances, it is important to learn to identify the right patients who are most likely to benefit from these therapies and determine where within the NSCLC treatment arsenal these therapies fit the best. Watch PeerView's latest educational video, based on a recent live symposium, which combines high-level seminars highlighting the latest evidence on HER2-, HER3-, and TROP2-targeting ADCs in NSCLC with a practicum dedicated to providing useful guidance on the implications and applications of the science to modern oncology practice to improve outcomes in patients with lung cancer. Upon completion of this activity, participants should be better able to: Discuss the frequency, role, and targetable potential of HER2, HER3, TROP2, and other alterations in NSCLC; Compare the characteristics, efficacy/safety, and ongoing investigations of emerging ADCs targeting HER2, HER3, TROP2, and other alterations in NSCLC; Apply the latest evidence and guidelines on patient assessment in NSCLC, including biomarker testing as indicated, to identify patients for targeted therapies, including emerging ADCs targeting HER2, HER3, TROP2, and other alterations in the context of a clinical trial; Utilize best practices for identifying and managing treatment-related adverse events in patients receiving targeted therapies for NSCLC to promote optimal adherence, outcomes, and quality of life

Go online to PeerView.com/FVE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Mounting evidence continues to support the clinical potential of antibody–drug conjugates (ADCs) in the treatment of patients with lung cancer, bringing hope to patients with limited treatment options. For example, novel HER2-targeting ADCs have demonstrated remarkable efficacy in advanced NSCLC, particularly in patients with HER2 mutations. ADCs targeting HER3, TROP2, and other alterations (eg, CEACAM5 and MET) are also producing promising data. In the context of these advances, it is important to learn to identify the right patients who are most likely to benefit from these therapies and determine where within the NSCLC treatment arsenal these therapies fit the best. Watch PeerView's latest educational video, based on a recent live symposium, which combines high-level seminars highlighting the latest evidence on HER2-, HER3-, and TROP2-targeting ADCs in NSCLC with a practicum dedicated to providing useful guidance on the implications and applications of the science to modern oncology practice to improve outcomes in patients with lung cancer. Upon completion of this activity, participants should be better able to: Discuss the frequency, role, and targetable potential of HER2, HER3, TROP2, and other alterations in NSCLC; Compare the characteristics, efficacy/safety, and ongoing investigations of emerging ADCs targeting HER2, HER3, TROP2, and other alterations in NSCLC; Apply the latest evidence and guidelines on patient assessment in NSCLC, including biomarker testing as indicated, to identify patients for targeted therapies, including emerging ADCs targeting HER2, HER3, TROP2, and other alterations in the context of a clinical trial; Utilize best practices for identifying and managing treatment-related adverse events in patients receiving targeted therapies for NSCLC to promote optimal adherence, outcomes, and quality of life

Go online to PeerView.com/FVE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Mounting evidence continues to support the clinical potential of antibody–drug conjugates (ADCs) in the treatment of patients with lung cancer, bringing hope to patients with limited treatment options. For example, novel HER2-targeting ADCs have demonstrated remarkable efficacy in advanced NSCLC, particularly in patients with HER2 mutations. ADCs targeting HER3, TROP2, and other alterations (eg, CEACAM5 and MET) are also producing promising data. In the context of these advances, it is important to learn to identify the right patients who are most likely to benefit from these therapies and determine where within the NSCLC treatment arsenal these therapies fit the best. Watch PeerView's latest educational video, based on a recent live symposium, which combines high-level seminars highlighting the latest evidence on HER2-, HER3-, and TROP2-targeting ADCs in NSCLC with a practicum dedicated to providing useful guidance on the implications and applications of the science to modern oncology practice to improve outcomes in patients with lung cancer. Upon completion of this activity, participants should be better able to: Discuss the frequency, role, and targetable potential of HER2, HER3, TROP2, and other alterations in NSCLC; Compare the characteristics, efficacy/safety, and ongoing investigations of emerging ADCs targeting HER2, HER3, TROP2, and other alterations in NSCLC; Apply the latest evidence and guidelines on patient assessment in NSCLC, including biomarker testing as indicated, to identify patients for targeted therapies, including emerging ADCs targeting HER2, HER3, TROP2, and other alterations in the context of a clinical trial; Utilize best practices for identifying and managing treatment-related adverse events in patients receiving targeted therapies for NSCLC to promote optimal adherence, outcomes, and quality of life

In this episode,Egbert F. Smit, MD, PhD; David Planchard, MD, PhD; and  Helena A. Yu, MD, answer audience questions from a live webinar regarding clinical data on antibody–drug conjugates in NSCLC including:Biopsies and biomarker testing considerationsTumor heterogeneity and targeting of brain metastasesLiquid biopsiesSequencing of ADCs following previous therapyToxicity managementPresenters:Egbert F. Smit, MD, PhDProfessorDepartment of Pulmonary DiseasesLeiden University Medical CenterLeiden, NetherlandsDepartment of Thoracic OncologyNetherlands Cancer InstituteAmsterdam, NetherlandsDavid Planchard, MD, PhDHead of Thoracic GroupDepartment of Medical OncologyInstitute Gustave RoussyVillejuif, FranceHelena A. Yu, MDAssistant AttendingDepartment of MedicineMemorial Sloan Kettering Cancer CenterNew York, New YorkContent based on an online CME program supported by an educational grant from Daiichi Sankyo, Inc.Congress to Clinic: Post-ELCC Updates on Antibody–Drug Conjugates in NSCLC - Oncology - Clinical Care Options (clinicaloptions.com)Link to full program:https://bit.ly/3fr2G6G